Arbutus Biopharma Corporation (NASDAQ: ABUS) has reported its financial results for the third quarter of 2025, along with a corporate update. The company's cash, cash equivalents, and marketable securities totaled $93.7 million as of September 30, 2025, compared to $122.6 million at the end of 2024. This reflects a decrease of $28.9 million in liquidity.
In terms of revenue, Arbutus reported total revenue of $0.5 million for the third quarter of 2025, down from $1.3 million for the same period in 2024. This decline was primarily due to a decrease in license royalty revenues, attributed to a decline in sales of Onpattro by Alnylam.
The company's research and development expenses for the third quarter of 2025 were $5.8 million, significantly lower than the $14.3 million reported for the same period in 2024. This reduction was attributed to cost savings from organizational streamlining efforts, including the discontinuation of certain clinical trials and workforce reductions.
General and administrative expenses for the third quarter of 2025 were $3.0 million, down from $4.5 million for the same period in 2024. This decrease was primarily driven by cost-cutting efforts, leading to reductions in employee compensation-related expenses and legal fees.
Arbutus reported a net loss of $7.7 million, or a loss of $0.04 per basic and diluted common share, for the third quarter of 2025, compared to a net loss of $19.7 million, or a loss of $0.10 per basic and diluted common share, for the same period in 2024.
As of September 30, 2025, Arbutus had 192.0 million common shares issued and outstanding, as well as 14.9 million stock options and unvested restricted stock units outstanding.
In addition to the financial results, Arbutus provided updates on its clinical programs, particularly highlighting the progress of its imdusiran (AB-729) therapy for chronic hepatitis B virus (HBV) infection. The company shared new analysis showing that 46% of all phase 2a patients were able to discontinue all treatment, with the majority remaining off all treatment long-term, some for over two years.
Furthermore, the company noted favorable developments in its legal disputes, with ongoing lawsuits against Moderna and Pfizer/BioNTech related to the unauthorized use of Arbutus's patented LNP technology.
Arbutus's strategic focus on advancing the clinical development of its therapeutic candidates, imdusiran and AB-101, is evident from the cost-saving measures and workforce streamlining efforts undertaken during the third quarter of 2025.
The financial and clinical updates provided by Arbutus demonstrate the company's efforts to advance its infectious disease-focused pipeline while actively managing its financial resources and addressing legal challenges. Following these announcements, the company's shares moved 2.76%, and are now trading at a price of $4.84. For the full picture, make sure to review Arbutus Biopharma Corp's 8-K report.
